TiLV Detection and Vaccine via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The decline in tilapia populations due to an unidentified infectious agent in both wild and farmed tilapia, affecting ecological balance and economic viability, necessitates the identification of the causal agent and development of diagnostic and protective measures.
Innovation Solution
The isolation and characterization of Tilapia Lake Virus (TiLV), along with the development of diagnostic tools, vaccines, and immunogenic compositions to detect and protect against TiLV, including nucleic acid sequences, peptides, antibodies, and iRNAs targeting TiLV, facilitate the detection and prevention of TiLV-induced disease in tilapia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If routine monitoring of known parasites, bacterial, and viral pathogens is performed, then standard disease detection protocols are followed, but the unidentified infectious agent causing tilapia population decline cannot be detected
Solution Approach 1:
The patent segments the disease detection process into multiple stages: initial routine monitoring using known pathogen protocols, followed by advanced molecular techniques (RT-PCR, sequencing) when population decline is observed but causative agent remains unidentified. This segmented approach allows maintaining standard protocols while adding specialized detection capabilities for emerging pathogens.
Solution Approach 2:
The patent develops universal diagnostic tools including broad-spectrum primers and probes that can detect multiple virus types, as well as TiLV-specific diagnostic assays. The immunogenic compositions and antibodies developed can be applied to both TiLV detection and broader viral disease surveillance, providing multi-functional detection capabilities.
2Reliability
If Tilapia Lake Virus (TiLV) is identified and characterized, then effective diagnostic tools and vaccines can be developed, but the complexity of viral characterization and tool development increases
Solution Approach 1:
The patent performs preliminary viral characterization including genome sequencing, protein identification, and antibody generation before developing diagnostic tools and vaccines. This preliminary characterization provides the foundation for subsequent diagnostic assay development, reducing overall system complexity by having all viral parameters established in advance.
Solution Approach 2:
The patent creates simplified copies and models including recombinant viral proteins, synthetic oligonucleotide probes, and monoclonal antibodies that replicate key viral features. These copies serve as targets for diagnostic assays and vaccine development, eliminating the need to handle complex live virus materials while maintaining diagnostic reliability.
3Object-affected harmful factors
If immunogenic compositions and vaccines are developed to protect tilapia from TiLV, then fish populations can be protected from disease, but the time and resources required for vaccine development and deployment increase
Solution Approach 1:
The patent conducts preliminary studies including viral isolation, genome characterization, and protein identification before initiating vaccine development. Antibodies are generated and characterized in advance, providing ready-to-use reagents for both diagnostic assays and vaccine formulations, thereby reducing overall development time.
Solution Approach 2:
The patent uses recombinant viral proteins and peptides as intermediaries in vaccine development. These purified protein components serve as safe and effective vaccine antigens, eliminating the need to work with live attenuated virus while providing sufficient immunogenicity. The intermediaries also serve as targets for antibody-based diagnostics and therapeutic interventions.
Data Source
AI summary
The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.